Candida auris 2026
About Candida auris
Why health officials are worried
Candida auris breaks the usual rules for a fungus. It passes from patient to patient inside healthcare facilities, lingers on bed rails and equipment for weeks, and shrugs off the antifungal drugs meant to treat it. The CDC ranks it an urgent antimicrobial-resistance threat, its highest tier. The good news for most people is that it is not a community threat: it targets the already seriously ill, not the healthy public.
Sources: CDC C. auris Tracking · CDC Infection Control
Treatments & Vaccines in Development
Candida auris is treated with antifungal drugs, but resistance is the whole problem: the first-line class still works against many strains, a growing share resist everything available, and there is no vaccine. Here is what care looks like.
Most Candida auris infections are treated first with an antifungal class called echinocandins (micafungin, caspofungin or anidulafungin), which still work against many strains. Treatment should be guided by an infectious-disease specialist and by lab tests showing which drugs the specific strain responds to.
CDC C. auris Treatment →When a strain resists echinocandins, or resists all three main antifungal classes, options run short. Doctors may turn to drug combinations or newer antifungals such as rezafungin, and others like ibrexafungerp and fosmanogepix are being studied. A small but growing number of strains are resistant to everything currently available, which is the core worry.
CDC Antifungal Resistance →There is no vaccine against Candida auris. Because it spreads inside healthcare facilities and clings to surfaces, the main defense is infection control: screening patients who may carry it, isolating those who do, strict hand hygiene, and cleaning with disinfectants proven to kill it.
CDC C. auris Infection Control →